Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth.
Home
Drugmaker GSK saw a sharp drop in revenue from its blockbuster Arexvy vaccine in the third quarter, dampening overall sales growth.
Free Netflix and Sky TV trial deal ends in hours – here’s how to claim it
Private sector grows steadily in May amid signs of cooling services inflation
Net migration to UK drops after hitting record levels, fuelling election debate
Ten Hag saves United career or City win double? – FA Cup final talking points
This will close in 0 seconds